Immuno-Biological Laboratories Co., Ltd.
Stock Price Chart
2026/08/26 UpdatedPrice Trend
2026/08/26 UpdatedPrice & Trading Details
2026/08/26 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Dividend History 1Years Growth
Updated 2026/08/23| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥6 | +20.0% |
| 2013 | ¥5 | - |
Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥795M | ¥817M | ¥970M | ¥1,005M |
| Gross Profit | ¥527M | ¥517M | ¥634M | ¥707M |
| Operating Income | ¥57M | ¥104M | ¥209M | ¥281M |
| Pretax Income | -¥280M | ¥126M | ¥211M | ¥302M |
| Net Income | -¥290M | ¥187M | ¥249M | ¥329M |
| EPS | -¥31.10 | ¥20.05 | ¥26.74 | ¥35.33 |
| Operating Margin | 7.19% | 12.77% | 21.59% | 27.99% |
| Balance Sheet | ||||
| Total Assets | ¥1,434M | ¥1,619M | ¥1,845M | ¥2,155M |
| Total Equity | ¥1,079M | ¥1,265M | ¥1,514M | ¥1,843M |
| Total Liabilities | ¥356M | ¥353M | ¥331M | ¥312M |
| Cash | ¥614M | ¥734M | ¥826M | ¥989M |
| Interest-bearing Debt | ¥235M | ¥236M | ¥204M | ¥177M |
| Equity Ratio | 75.20% | 78.17% | 82.06% | 85.53% |
| D/E Ratio | 0.22 | 0.19 | 0.13 | 0.10 |
| Cash Flow | ||||
| Operating CF | ¥26M | ¥134M | ¥183M | ¥301M |
| Investing CF | ¥30M | -¥24M | -¥54M | -¥116M |
| Financing CF | ¥1M | ¥1M | -¥32M | -¥27M |
| Free CF | ¥26M | ¥115M | ¥124M | ¥268M |
| Efficiency | ||||
| ROE | -26.86% | 14.75% | 16.45% | 17.85% |
| ROA | -20.20% | 11.53% | 13.50% | 15.27% |
Latest IR Information
-
(Disclosure Items Progress) Notice regarding GLP-compliant repeated dosing toxicity test of anti-HIV antibody
The animal study portion of the GLP-compliant repeated dosing toxicity test for the anti-HIV antibody related to jointly held patents has finished. The final report is being compiled by the institution, and NOAEL assessments will be confirmed after receipt and...
Read more -
Notice Regarding the Status and Schedule of HIV Antibody Development
Read more
Latest News (5 items)
Company Information
About
Immuno-Biological Laboratories Co., Ltd. engages in the research, development, manufacturing, and supply of various immunological research reagents worldwide. The company offers ELILSA, an assay kit to quantitatively measure targeted substances; and support research services on Alzheimer's disease, metabolic syndrome, and cancer, as well as customized services for production of customized antibodies and development of ELISA systems. It also provides LipoSEARCH, a customized services for profiling and analyzing of lipoprotein through gel-filtration high performance liquid chromatography method that can profile various clinical samples, such as tiny plasma or serum samples from both small animals and human beings for broad range of research fields including lipid metabolism, development of drugs for life-style related diseases, development of functional supplemental foods, and clinical studies. In addition, the company offers LipoTEST, a support tool for diagnostic and health checks at animal clinics; and customized biomarker testing services for Life-style related diseases. Further, it operates protein production business using transgenic silkworms for manufacturing of antibodies for research reagents and diagnostic products; human collagen for cosmetic materials; development of proteins for use in drugs; and other proteins production. The company was incorporated in 1982 and is headquartered in Fujioka, Japan.